Richard Nathan

TL;DR: Among participants receiving antibiotic treatment for primary or recurrent C. difficile infection, bezlotoxumab was associated with a substantially lower rate of recurrent infection than placebo and had a safety profile similar to that of placebo.

TL;DR: Rinilazole is a targeted-spectrum antimicrobial that shows potential in treatment of initial C difficile infection and in providing sustained benefit through reduction in disease recurrence through statistical superiority at the 10% level.

TL;DR: Combined data from 2 double-blind, randomized, phase 3 studies in adult patients receiving oral standard of care (SoC) for primary or recurrent Cd ifficile infection (rCDI), including multiple rCDI, show global cure and safety endpoints were comparable for ACT + BEZ and BEZ alone versus placebo.

TL;DR: In this post hoc analysis of participants with cancer enrolled in MODIFY I/II, the rate of rCDI in bezlotoxumab- treated participants was lower than in placebo-treated participants.

TL;DR: In this first phase 1b study of a fermented microbiome drug in subjects with primary CDI, SER-262 was safe and well-tolerated and the impact of dysbiosis on engraftment may be due to low baseline microbial diversity, which creates an ecologic niche for greater engraftments of dose species.